Scholar Rock to Present New Data from Phase 1 DRAGON Trial at SITC
Scholar Rock, a late-stage biopharmaceutical company specializing in treatments for serious diseases like spinal muscular atrophy (SMA), cardiometabolic disorders,...
Adaptive Clinical Trial Design Adaptive Trial Design AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies DOGE FDA Budget Cuts eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy manufacturing compliance Oncology Trials Opinion Parkinson's Disease Patient Stratification Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
Scholar Rock, a late-stage biopharmaceutical company specializing in treatments for serious diseases like spinal muscular atrophy (SMA), cardiometabolic disorders,...
Bristol Myers Squibb recently unveiled positive topline results from two Phase 3 open-label trials, EMERGENT-4 and EMERGENT-5. These trials...
Mirum Pharmaceuticals will participate in the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) annual meeting from...
ChromaDex Corp. reported strong third-quarter 2024 financial results, marked by record revenue, net income, and adjusted EBITDA. The company...
KORU Medical Systems presented data at the 2024 PODD Conference showcasing nurse preference for the KORU FreedomEdge® Infusion System...
Verastem Oncology has completed its New Drug Application (NDA) to the U.S. FDA for a combination therapy targeting recurrent...
Synedgen, Inc., a biotechnology company specializing in gastrointestinal disease treatment, has secured a $2.2 million contract from the Joint...
Lucent Diagnostics has launched LucentAD Complete, a novel multi-marker blood test designed to enhance the detection of Alzheimer’s Disease...
Elixir Medical, a company dedicated to developing innovative treatments for cardiovascular diseases, has released promising data from its INFINITY-SWEDEHEART...
A recent study published in The Journal of Clinical Pharmacology reveals that intramuscular nalmefene effectively reverses fentanyl-induced respiratory depression....